liraglutide weight loss (NN2211) is a long-acting glucagon-like peptide-1 receptor agonist, binding to the same receptors as does the endogenous metabolic hormone

GLP-1 that stimulates insuli n secretion. Marketed under the brand name Victoza, it is developed by Novo Nordisk for the treatment oftype 2 diabetes. In 2015, Novo Nordisk began marketing it in the U.S. and E.U. under the brand name Saxenda
as a treatment for adults, who are obese or overweight with at least one weight-relatedcomorbid condition.

Liraglutide is a long-acting glucagon-like peptide-1 receptor agonist, binding to the same receptors as does the endogenous metabolic hormone GLP-1 that stimulates insuli n secretion.